Treatment for Advanced-stage HCC

The treatment for advanced stage HCC is changing with the FDA approval of multiple treatments over the last few years. Currently we have two treatment options (Sorafenib or Lenvatinib) for patients who have been untreated for advanced HCC. Four treatment options (Regorafenib, Nivolumab, Pembrolizumab, Cabozantinib) are approved for patients who have received one line of prior therapy for advanced HCC.
More videos: https://ruesch.georgetown.edu/rueschr...

Transcript:
The treatment landscape for advanced stage HCC is evolving quickly in front of our eyes. Currently, there are four approved treatments. The first therapy, sorafenib, was approved over 10 years ago in 2007. We've only had this one systemic therapy for over 10 years. In 2017, two additional therapies have been approved in this disease. First is regorafenib. Second is nivolumab. In this year, 2018, another therapy, lenvatinib, has been approved by FDA for the treatment of advanced stage HCC.

Now, in the front line setting, we have two approved drug, sorafenib and lenvatinib. Both are multi-thyrase and kinase inhibitors, though oral agents. In the second-line setting, in patients who have progressed or cannot tolerate the first-line therapy, we have regorafenib and nivolumab. Regorafenib is another multikinase inhibitor, is a oral agent. Nivolumab works differently. It's immune checkpoint inhibitors. It's FDA approve for durable response. The three multikinase inhibitors sorafenib, regorafenib, and lenvatinib, are FDA approved for prolongation of survival in patients with advanced stage HCC.